A bipartisan and bicameral group of U.S. lawmakers released its Request for Information (RFI) on the federal regulation of cannabidiol, also known as CBD, Thursday.
The group includes Senate Health, Education, Labor and Pensions Committee Chair Bernie Sanders (I-Vt.) and ranking member Bill Cassidy (R-La.) as well as House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-Wash.) and ranking member Frank Pallone Jr. (D-N.J.).
An RFI is a research tool that outsources knowledge regarding the capabilities, best practices, rules and regulations of a specific service or agency from experts in related industries, research bodies and organizations.
In the request, the group asks “subject matter experts and stakeholders” to provide them with information like a description of what “the current market for CBD products” looks like and in what ways “the absence of federal regulation over CBD created a market for intoxicating, synthetically-produced compounds.”
“In January 2023, FDA [Food and Drug Administration] announced that it would like to work with Congress to craft a legislative approach to the regulation of CBD products,” the request reads. “We are assessing the potential for a regulatory pathway for hemp-derived CBD products that prioritizes consumer safety and provides certainty to the U.S. market. We look forward to working with interested stakeholders on this process, and we ask for written responses on the following…
